Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613815 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HTR2CDRD2TSHRCYP1A1 | |
| SCHEMBL12297790 | 0.83 | HTR2C (0.50) | ALDH1A1HTR2CDRD2TSHRCYP1A1 | |
| SCHEMBL1366191 | 0.82 | HTR2C (0.66) | HTR2CDRD2 | |
| SCHEMBL17514730 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HTR2CDRD2TSHRCYP1A1 | |
| SCHEMBL20789976 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HTR2CDRD2TSHRCYP1A1 | |
| SCHEMBL240094 | 0.80 | DRD2 (0.51) | ALDH1A1DRD2MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7723674 | 0.79 | ALDH1A1 (0.48) | ALDH1A1HTR2CDRD2TSHRCYP1A1 | |
| SCHEMBL1363978 | 0.77 | PTAFR (0.33) | ALDH1A1HTR2CTSHRMAPT | |
| SCHEMBL5584986 | 0.77 | PTAFR (0.53) | ALDH1A1TSHRKDM4EMAPTMEN1 | |
| SCHEMBL5543998 | 0.77 | PARP1 (0.42) | ALDH1A1HTR2CKDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | ALDH1A1 443/4885HTR2C 9/4885DRD2 62/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | ALDH1A1 443/4885HTR2C 9/4885DRD2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.